Mirum SVP sells 2,721 shares in planned trade

Mirum Pharmaceuticals SVP and global controller Jolanda Howe reported an open-market sale of 2,721 shares of common stock at $120.00 per share.

Rhea-AI Filing Summary

Mirum Pharmaceuticals SVP and global controller Jolanda Howe reported an open-market sale of 2,721 shares of common stock at $120.00 per share. After the transaction, she directly holds 3,114 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating it was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 2,721 shares

Net Sell 1 txn

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 2,721 shs ($327K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,721	$120.00	$327K

Holdings After Transaction: Common Stock — 3,114 shares (Direct)

Footnotes (1)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

Key Figures

Shares sold: 2,721 shares Sale price: $120.00 per share Shares held after sale: 3,114 shares +1 more

4 metrics

Shares sold 2,721 shares Open-market sale of common stock on July 1, 2026

Sale price $120.00 per share Price for the 2,721 Mirum common shares sold

Shares held after sale 3,114 shares Direct ownership following the reported transaction

Net share change -2,721 shares Net selling activity in this Form 4

Key Terms

Rule 10b5-1 Plan, open-market sale, Form 4, Common Stock, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code "S" regulatory

"transaction_code: "S""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mirum Pharmaceuticals (MIRM) report for Jolanda Howe?

Mirum Pharmaceuticals reported that SVP and global controller Jolanda Howe sold 2,721 shares of common stock in an open-market transaction at $120.00 per share, and continues to hold 3,114 shares directly following this planned sale.

Was the Mirum Pharmaceuticals (MIRM) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the reported transaction occurred under a Rule 10b5-1 trading plan adopted by Jolanda Howe on March 18, 2026, indicating the sale was pre-scheduled rather than timed in response to short-term market or company developments.

How many Mirum Pharmaceuticals (MIRM) shares did Jolanda Howe sell and at what price?

Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals common stock at a price of $120.00 per share. This was an open-market sale and was the only reported transaction in this Form 4 filing for the stated date.

How many Mirum Pharmaceuticals (MIRM) shares does Jolanda Howe hold after the sale?

Following the reported sale, Jolanda Howe directly holds 3,114 shares of Mirum Pharmaceuticals common stock. This post-transaction ownership figure is disclosed in the Form 4 and reflects her remaining direct position after the 2,721-share disposition.

What type of transaction code was used in the Mirum Pharmaceuticals (MIRM) Form 4?

The Form 4 uses transaction code “S,” which indicates a sale of non-derivative securities, such as common stock, in an open-market or private transaction. In this case, it reflects the open-market sale of 2,721 Mirum Pharmaceuticals shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 06:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GLOBAL CONTROLLER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		2,721	D	$120	3,114	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

	/s/ Judit Ryvkin, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)